Suppr超能文献

LKB1 通过组蛋白乳酰化抑制端粒酶活性,导致肺腺癌中的细胞衰老。

LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma.

机构信息

Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, Jilin, China.

Department of Urology, the First Hospital of Jilin University, Changchun, 130021, Jilin, China.

出版信息

Cancer Lett. 2024 Jul 28;595:217025. doi: 10.1016/j.canlet.2024.217025. Epub 2024 Jun 4.

Abstract

Despite the confirmed role of LKB1 in suppressing lung cancer progression, its precise effect on cellular senescence is unknown. The aim of this research was to clarify the role and mechanism of LKB1 in restraining telomerase activity in lung adenocarcinoma. The results showed that LKB1 induced cellular senescence and apoptosis either in vitro or in vivo. Overexpression of LKB1 in LKB1-deficient A549 cells led to the inhibition of telomerase activity and the induction of telomere dysfunction by regulating telomerase reverse transcriptase (TERT) expression in terms of transcription. As a transcription factor, Sp1 mediated TERT inhibition after LKB1 overexpression. LKB1 induced lactate production and inhibited histone H4 (Lys8) and H4 (Lys16) lactylation, which further altered Sp1-related transcriptional activity. The telomerase inhibitor BIBR1532 was beneficial for achieving the optimum curative effect of traditional chemotherapeutic drugs accompanied by the glycolysis inhibitor 2DG. These data reveal a new mechanism by which LKB1 regulates telomerase activity through lactylation-dependent transcriptional inhibition, and therefore, provide new insights into the effects of LKB1-mediated senescence in lung adenocarcinoma. Our research has opened up new possibilities for the creation of new cancer treatments.

摘要

尽管 LKB1 已被证实可抑制肺癌的进展,但它对细胞衰老的确切作用尚不清楚。本研究旨在阐明 LKB1 在抑制肺腺癌端粒酶活性中的作用和机制。结果表明,LKB1 无论是在体外还是体内都能诱导细胞衰老和凋亡。在 LKB1 缺失的 A549 细胞中过表达 LKB1 会通过调节端粒酶逆转录酶(TERT)的表达来抑制端粒酶活性并诱导端粒功能障碍,从而实现转录调控。作为一种转录因子,Sp1 在 LKB1 过表达后介导 TERT 的抑制。LKB1 诱导乳酸生成并抑制组蛋白 H4(Lys8)和 H4(Lys16)的乳酰化,从而进一步改变 Sp1 相关的转录活性。端粒酶抑制剂 BIBR1532 有利于与糖酵解抑制剂 2DG 一起实现传统化疗药物的最佳疗效。这些数据揭示了 LKB1 通过依赖乳酰化的转录抑制来调节端粒酶活性的新机制,从而为 LKB1 介导的肺腺癌衰老的影响提供了新的见解。我们的研究为创造新的癌症治疗方法开辟了新的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验